Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting cGAS
- Development stage
- Preclinical
- Lead developer
- Hiroshima University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siRNA targeting cGAS refers to small interfering RNA molecules designed to silence the expression of cyclic GMP-AMP synthase (cGAS), a critical cytosolic DNA sensor. cGAS is responsible for detecting double-stranded DNA in the cytoplasm, which can occur due to DNA damage, cellular senescence, or viral infection. Upon activation, cGAS produces the second messenger cyclic GMP-AMP (cGAMP), which subsequently activates the Stimulator of Interferon Genes (STING) pathway. This pathway triggers the production of Type I interferons and other proinflammatory cytokines, such as IL-6 and MCP-1. In research settings, cGAS siRNA is utilized to investigate the role of this pathway in inflammatory conditions like atherosclerosis, where DNA damage accumulation promotes vascular inflammation. By degrading cGAS mRNA via the RNA interference (RNAi) pathway, these siRNA agents effectively inhibit the downstream inflammatory response.
- Other names
- cGAS siRNAsiRNA-cGAS
02
Targets
Cyclic GMP–AMP synthaseCyclic GMP-AMP synthase mRNA
Beyond the preview
Go deeper on siRNA targeting cGAS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting cGAS.